{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:02:36Z","timestamp":1793329356293,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Gout is the most common inflammatory arthritis worldwide and is the only type of chronic arthritis that potentially can be \u2018cured\u2019. However, data on gout incidence, prevalence and management, assessed at multiple time points in the same population, are sparse, particularly in Asian populations. The aim of this study was to describe trends in the epidemiology of gout in the general population of Taiwan.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The National Health Insurance Research Database was used to identify patients with gout and to estimate the prevalence and incidence of gout for each calendar year from 2005 to 2010. The pattern of gout management was also examined.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Of 23,371,362 beneficiaries in 2010, there were 1,458,569 prevalent and 56,595 incident cases of gout, giving a prevalence of 6.24% (95% confidence interval (CI), 6.23% to 6.25%) and an incidence of 2.74 (95% CI, 2.72 to 2.76) per 1,000 person-years. The annual percentage change (APC) of the standardised prevalence was \u22120.7% (95% CI, \u22121.7% to 0.3%; <jats:italic>P<\/jats:italic> = 0.14), suggesting that the prevalence of gout was essentially the same throughout the study period. However, The APC of incidence was \u221213.4 (95% CI, \u221216.1 to \u221210.6) between 2005 and 2007 and \u22122.1 (95% CI, \u221210.4 to 7.1) between 2007 and 2010. Regions with the highest prevalence and incidence were eastern coastal counties and offshore islets, where indigenous people are clustered. Among prevalent gout cases in 2010, only 22.93% (95% CI, 22.87% to 23.00%) were prescribed urate-lowering treatment (ULT), which remained unchanged between 2005 and 2010 at an APC of 0.0 (95% CI, \u22123.8 to 4.0). Uricosuric agents were more commonly prescribed than xanthine oxidase inhibitors in Taiwan.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>In Taiwan, 1 in 16 people have gout. Whereas the incidence has decreased recently, the prevalence remains unchanged. Management of gout in Taiwan is poor, with only one in five affected people being treated with ULT.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0522-8","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T12:35:00Z","timestamp":1421843700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Epidemiology and management of gout in Taiwan: a nationwide population study"],"prefix":"10.1186","volume":"17","author":[{"given":"Chang-Fu","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Grainge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai-Chu","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shue-Fen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,23]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","volume":"73","author":"E Smith","year":"2014","unstructured":"Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470\u20136. doi:10.1136\/annrheumdis-2013-204647.","journal-title":"Ann Rheum Dis"},{"key":"522_CR2","volume-title":"Crystal-induced arthropathies: gout, pseudogout, and apatite-associated syndromes","year":"2006","unstructured":"Wortmann RL, Schumacher HR, Becker MA, Ryan LM, editors. Crystal-induced arthropathies: gout, pseudogout, and apatite-associated syndromes. New York: Taylor & Francis; 2006."},{"key":"522_CR3","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765\u201370.","journal-title":"Ann Rheum Dis"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jbspin.2011.01.007","volume":"78","author":"CF Kuo","year":"2011","unstructured":"Kuo CF, Yu KH, See LC, Chou IJ, Tseng WY, Chang HC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine. 2011;78:577\u201380.","journal-title":"Joint Bone Spine"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","volume":"49","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49:141\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894\u2013900.","journal-title":"Circulation"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ncprheum0556","volume":"3","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443\u20139.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"522_CR8","doi-asserted-by":"crossref","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014. doi:10.1136\/annrheumdis-2013-204463.","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136\u201341.","journal-title":"Arthritis Rheum"},{"key":"522_CR10","first-page":"302","volume":"21","author":"CT Chou","year":"1994","unstructured":"Chou CT, Pei L, Chang DM, Lee CF, Schumacher HR, Liang MH. Prevalence of rheumatic diseases in Taiwan: a population study of urban, suburban, rural differences. J Rheumatol. 1994;21:302\u20136.","journal-title":"J Rheumatol"},{"key":"522_CR11","first-page":"1364","volume":"24","author":"SJ Chang","year":"1997","unstructured":"Chang SJ, Ko YC, Wang TN, Chang FT, Cinkotai FF, Chen CJ. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol. 1997;24:1364\u20139.","journal-title":"J Rheumatol"},{"key":"522_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/rheumatology\/37.3.258","volume":"37","author":"CT Chou","year":"1998","unstructured":"Chou CT, Lai JS. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol. 1998;37:258\u201362.","journal-title":"Br J Rheumatol"},{"key":"522_CR13","first-page":"1045","volume":"27","author":"KC Lin","year":"2000","unstructured":"Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol. 2000;27:1045\u201350.","journal-title":"J Rheumatol"},{"key":"522_CR14","first-page":"1640","volume":"28","author":"HY Chang","year":"2001","unstructured":"Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol. 2001;28:1640\u20136.","journal-title":"J Rheumatol"},{"key":"522_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/SMJ.0b013e3181a8cab9","volume":"102","author":"SW Lai","year":"2009","unstructured":"Lai SW, Liu CS, Lin T, Lin CC, Lai HC, Liao KF. Prevalence of gout and hyperuricemia in Taiwan: a hospital-based, cross-sectional study. South Med J. 2009;102:772\u20133.","journal-title":"South Med J"},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3109\/03009741003742797","volume":"39","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, Yu KH, Luo SF, Chiu CT, Ko YS, Hwang JS, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol. 2010;39:466\u201371.","journal-title":"Scand J Rheumatol"},{"key":"522_CR17","first-page":"301","volume":"20","author":"SY Chuang","year":"2011","unstructured":"Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr. 2011;20:301\u20138.","journal-title":"Asia Pac J Clin Nutr"},{"key":"522_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1136\/annrheumdis-2013-204067","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Valdes AM, et al. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. Ann Rheum Dis. 2015;74:369\u201374. doi:10.1136\/annrheumdis-2013-204067.","journal-title":"Ann Rheum Dis"},{"key":"522_CR19","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1371\/journal.pgen.0040019","volume":"4","author":"JS Friedlaender","year":"2008","unstructured":"Friedlaender JS, Friedlaender FR, Reed FA, Kidd KK, Kidd JR, Chambers GK, et al. The genetic structure of Pacific Islanders. PLoS Genet. 2008;4:e19.","journal-title":"PLoS Genet"},{"key":"522_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/ard.56.1.22","volume":"56","author":"P Klemp","year":"1997","unstructured":"Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56:22\u20136.","journal-title":"Ann Rheum Dis"},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-55-2-179","volume":"55","author":"TF Yu","year":"1961","unstructured":"Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout: prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179\u201392.","journal-title":"Ann Intern Med"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335\u201351.","journal-title":"Stat Med"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3899\/jrheum.100418","volume":"38","author":"MA McAdams","year":"2011","unstructured":"McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, et al. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011;38:135\u201341.","journal-title":"J Rheumatol"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/ard.62.7.644","volume":"62","author":"HS Picavet","year":"2003","unstructured":"Picavet HS, Hazes JM. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis. 2003;62:644\u201350.","journal-title":"Ann Rheum Dis"},{"key":"522_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/ard.31.3.166","volume":"31","author":"JB O'Sullivan","year":"1972","unstructured":"O'Sullivan JB. Gout in a New England town: a prevalence study in Sudbury, Massachusetts. Ann Rheum Dis. 1972;31:166\u20139.","journal-title":"Ann Rheum Dis"},{"key":"522_CR26","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403\u20136.","journal-title":"J Rheumatol"},{"key":"522_CR27","doi-asserted-by":"crossref","unstructured":"Usbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237\u201342.","DOI":"10.1016\/0895-4356(88)90127-8"},{"key":"522_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.1780380508","volume":"38","author":"MC Hochberg","year":"1995","unstructured":"Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38:628\u201332.","journal-title":"Arthritis Rheum"},{"key":"522_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/rheumatology\/29.6.485","volume":"29","author":"OJ Stewart","year":"1990","unstructured":"Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases\u20134. Gout. Br J Rheumatol. 1990;29:485\u20138.","journal-title":"Br J Rheumatol"},{"key":"522_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/ard.2004.024091","volume":"64","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher Jr HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64:267\u201372.","journal-title":"Ann Rheum Dis"},{"key":"522_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/aje\/kwt299","volume":"179","author":"JW Maynard","year":"2014","unstructured":"Maynard JW, McAdams-Demarco MA, Law A, Kao L, Gelber AC, Coresh J, et al. Racial differences in gout incidence in a population-based cohort: atherosclerosis risk in communities study. Am J Epidemiol. 2014;179:576\u201383.","journal-title":"Am J Epidemiol"},{"key":"522_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/rheumatology\/keg035","volume":"42","author":"KH Yu","year":"2003","unstructured":"Yu KH, Luo SF. Younger age of onset of gout in Taiwan. Rheumatology (Oxford). 2003;42:166\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"522_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0002-9343(67)90004-6","volume":"42","author":"AP Hall","year":"1967","unstructured":"Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med. 1967;42:27\u201337.","journal-title":"Am J Med"},{"key":"522_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-1-4615-9140-5_8","volume":"122A","author":"N Nishioka","year":"1980","unstructured":"Nishioka N, Mikanagi K. Clinical features of 4,000 gouty subjects in Japan. Adv Exp Med Biol. 1980;122A:47\u201354.","journal-title":"Adv Exp Med Biol"},{"key":"522_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/rheumatology\/ker370","volume":"51","author":"R Li","year":"2012","unstructured":"Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 2012;51:721\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"522_CR36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/15257770.2011.633955","volume":"30","author":"T Hosoya","year":"2011","unstructured":"Hosoya T, Ohno I, Ichida K, Peters GJ. Gout and hyperuricemia in Japan: perspectives for international research on purines and pyrimidines in man. Nucleosides Nucleotides Nucleic Acids. 2011;30:1001\u201310.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"522_CR37","first-page":"837","volume":"29","author":"YC Ko","year":"2002","unstructured":"Ko YC, Wang TN, Tsai LY, Chang FT, Chang SJ. High prevalence of hyperuricemia in adolescent Taiwan aborigines. J Rheumatol. 2002;29:837\u201342.","journal-title":"J Rheumatol"},{"key":"522_CR38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/oxfordjournals.aje.a113043","volume":"112","author":"J Freeman","year":"1980","unstructured":"Freeman J, Hutchison GB. Prevalence, incidence and duration. Am J Epidemiol. 1980;112:707\u201323.","journal-title":"Am J Epidemiol"},{"key":"522_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2307\/2532312","volume":"48","author":"JM Alho","year":"1992","unstructured":"Alho JM. On prevalence, incidence, and duration in general stable populations. Biometrics. 1992;48:587\u201392.","journal-title":"Biometrics"},{"key":"522_CR40","unstructured":"Tsay GJ, Yu KH, Liang TH, Tsai W-C, Wei CC, Hsieh TY. Taiwan guideline for the management of gout and hyperuricaemia. Taipei: Taiwan Rheumatology Association; 2007. http:\/\/imohw.tmu.edu.tw\/idohtmu\/wp-content\/uploads\/2013\/04\/04%E5%8F%B0%E7%81%A3%E7%97%9B%E9%A2%A8%E8%88%87%E9%AB%98%E5%B0%BF%E9%85%B8%E8%A1%80%E7%97%87%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95.pdf. Accessed 10 Feb 2015."},{"key":"522_CR41","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford). 2005;44:1038\u201342.","journal-title":"Rheumatology (Oxford)"},{"key":"522_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/rheumatology\/kep332","volume":"49","author":"E Roddy","year":"2010","unstructured":"Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010;49:105\u201311.","journal-title":"Rheumatology (Oxford)"},{"key":"522_CR43","first-page":"104","volume":"33","author":"T Neogi","year":"2006","unstructured":"Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33:104\u20139.","journal-title":"J Rheumatol"},{"key":"522_CR44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.081296","volume":"36","author":"C Barber","year":"2009","unstructured":"Barber C, Thompson K, Hanly JG. Impact of a rheumatology consultation service on the diagnostic accuracy and management of gout in hospitalized patients. J Rheumatol. 2009;36:1699\u2013704.","journal-title":"J Rheumatol"},{"key":"522_CR45","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925\u201334.","journal-title":"Mayo Clin Proc"},{"key":"522_CR46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1071\/HC14073","volume":"6","author":"E Reaves","year":"2014","unstructured":"Reaves E, Arroll B. Management of gout in a South Auckland general practice. J Prim Health Care. 2014;6:73\u20138.","journal-title":"J Prim Health Care"},{"key":"522_CR47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1471-2474-13-174","volume":"13","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. BMC Musculoskelet Disord. 2012;13:174.","journal-title":"BMC Musculoskelet Disord"},{"key":"522_CR48","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66:1311\u20135.","journal-title":"Ann Rheum Dis"},{"key":"522_CR49","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","volume":"71","author":"K Spencer","year":"2012","unstructured":"Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71:1490\u20135.","journal-title":"Ann Rheum Dis"},{"key":"522_CR50","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jbspin.2011.05.010","volume":"78","author":"G Reach","year":"2011","unstructured":"Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78:456\u20139.","journal-title":"Joint Bone Spine"},{"key":"522_CR51","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67:609\u201313.","journal-title":"Ann Rheum Dis"},{"key":"522_CR52","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826\u201330.","journal-title":"Ann Rheum Dis"},{"key":"522_CR53","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895\u2013900.","journal-title":"Arthritis Rheum"},{"key":"522_CR54","volume-title":"The epidemiology of chronic rheumatism","year":"1963","unstructured":"Kellgren JH, Jeffrey MR, Ball J, editors. The epidemiology of chronic rheumatism. Oxford: Blackwell; 1963."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0522-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0522-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0522-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:30:02Z","timestamp":1728923402000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0522-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0522-8","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,23]]},"assertion":[{"value":"3 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"13"}}